Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113908 | 0.86 | ACHE (0.42) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL834995 | 0.84 | ACHE (0.43) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL21003496 | 0.83 | ACHE (0.39) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL9278459 | 0.81 | ACHE (0.45) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13819872 | 0.80 | MGAT2 (0.37) | HRH3HTTTSHRNPSR1 | |
| SCHEMBL17095988 | 0.80 | GNAI3 (0.41) | — | |
| SCHEMBL23811427 | 0.80 | ACHE (0.41) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18069368 | 0.80 | ACHE (0.41) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL16095435 | 0.78 | GNAO1 (0.31) | — | |
| SCHEMBL16095678 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9745271-B2 | 5-substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2017-08-29 | — | — | US | disclosed |
| US-9682965-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2015143380-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-09-24 | — | — | US | disclosed |
| US-8975250-B2 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | SANOFI (FR) | 2015-03-10 | — | — | US | disclosed |
| US-8975250-B2 | 5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases | SANOFI (FR) | 2015-03-10 | — | — | US | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2011086306-A9 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011086306-A1 | 5-OXO-5, 8-DIHYDROPYRIDO [2, 3-D] PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ACHE 239/4885CARM1 1765/4885PRMT6 813/4885 |
| US-20150266825-A1 | 5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, WNT1 | ACHE 1743/4885CARM1 2197/4885PRMT6 2760/4885 |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ACHE 239/4885CARM1 1765/4885PRMT6 813/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ACHE 1176/4885CARM1 1010/4885PRMT6 805/4885 |
| US-20120277220-A1 | 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CAMKK1, CAMKK2, CAMK1 | ACHE 3302/4885CARM1 3473/4885PRMT6 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.